Bristol-Myers Announces Positive Results From CheckMate -066 Study For Melanoma

(RTTNews) - Bristol-Myers Squibb Company (BMY) announced results from CheckMate -066, a Phase 3 randomized double blind study, comparing Opdivo, an investigational PD-1 immune checkpoint inhibitor, to the chemotherapy dacarbazine in patients with treatment naïve BRAF wild-type advanced melanoma.

The company said that the study met the primary endpoint of overall survival with the median OS not reached for Opdivo vs. 10.8 months for DTIC. The one-year survival rate was 73% for Opdivo vs. 42% for DTIC and there was a 58% decrease in the risk of death for patients treated with Opdivo.

This survival advantage was also observed in Opdivo-treated patients in both PD-L1 positive and PD-L1 negative patients.